

Management of Solitary Supratentorial Metastatic Brain Tumours

Thesis

Submitted in Partial Fulfillment of the Master Degree
In Neurosurgery

By

Hussam Ed-din Mohammed Al-Molakkab Sabry
(M.B., B.CH.)

Supervised by

Prof. Dr. Hazem Abd El sattar Abo Alnasr
Professor of Neurosurgery
Cairo University

Prof. Dr. Ahmed Abd Al Aziz Hegazy
Professor of Neurosurgery
Cairo University

Lecturer. Walid Eissa Al Halaby
Lecturer of Neurosurgery
Cairo University

Faculty of Medicine
Cairo University
2016

List of Contents

<i>Title</i>	<i>Page No.</i>
Introduction	1
Aim of the Work	7
Review of Literature:	
• Chapter (1): Biology and Pathology	8
• Chapter (2): Diagnosis	26
• Chapter (3): Management	59
Patients and Methods	87
Results	93
Case Presentation	101
Discussion	126
Summary	130
References	131
Arabic Summary	—

List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure 1:	Infiltrating Lobular Carcinoma of the Breast	25
Figure 2:	Single brain metastasis of breast carcinoma	35
Figure 3:	Melanoma metastases	37
Figure 4:	Radiation Necrosis (PET proven) Axial T2W1	45
Figure 5:	Late diffuse radiation injury. Axial MR: T2W1 (A,B) show symmetrical, bifrontal periventricular white matter hyperintensity without mass effect	45
Figure 6:	Preoperative Sagittal MRI T1W1 with contrast showing lesion	102
Figure 7:	Preoperative axial MRI T1W1 with contrast showing lesion	102
Figure 8:	Preoperative axial MRI T2W1 showing lesion	103
Figure 9:	Postoperative CT brain after one month showing total removal of mass	103
Figure 10:	Postoperative MRI T2W1 after 1 year showing total removal of mass	104
Figure 11:	Postoperative Sagittal MRI T1W1 with contrast showing total removal of mass	104

Figure 12: Postoperative axial MRI T1W1 with contrast showing total removal of mass	105
Figure 13: Follow up axial MRI T1W1 with contrast after 20 months showing tumor recurrence	105
Figure 14: Follow up Sagittal MRI T1W1 with contrast after 20 months showing tumor recurrence	106
Figure 15: Thallium Scan showing activity of lesion	106
Figure 16: MRI spectroscopy showing tumor activity	107
Figure 17: MRI spectroscopy showing tumor activity	107
Figure 18: Follow up Sagittal MRI T1W1 with contrast after 24 months showing increase in tumor size and new lesions ..	108
Figure 19: Follow up Sagittal MRI T1W1 with contrast after 24 months showing increase in tumor size and new lesions ..	108
Figure 20: Follow up axial MRI T1W1 with contrast after 24 months showing increase in tumor size and new lesions	109
Figure 21: Preoperative Axial MRI T1W1 with contrast showing the lesion	111
Figure 22: Preoperative Sagittal MRI T1W1 with contrast showing the lesion	111
Figure 23: Preoperative Coronal MRI T1W1 with contrast showing the lesion	112

Figure 24: Postoperative axial CT with and without contrast showing total removal of mass with persistant edema	112
Figure 25: Postoperative axial MRI T1W1 showing total tumor removal	113
Figure 26: Postoperative axial MRI T1W1 with contrast showing total tumor removal	113
Figure 27: Postoperative sagittal MRI T1W1 showing total tumor removal	114
Figure 28: Postoperative coronal. 1 MRI T1W1 showing total tumor removal	114
Figure 29: Postoperative axial MRI T1W1 showing total tumor removal	115
Figure 30: MRI brain axial cuts T1 with contrast (Preoperative)	117
Figure 31: Preoperative MRI brain coronal cutsT2, T1 with contrast	118
Figure 32: Preoperative MRI brain sagittal cuts T2, T1 with contrast	119
Figure 33: Post.operative CT brain axial cuts with and without contrast shows total removal with small haematoma in the tumor bed	121
Figure 34: Follow up MRI brain T2, Flair sequences axial cuts, after 1 year of surgery and full sessions of radiotherapy, shows no recurrence	122

Figure 35: MRI brain axial cuts, diffusion weighted image, after one year of tumour excision	123
Figure 36: MRI brain coronal cuts T2 and T1 with contrast 1 year after surgery	124
Figure 37: MRI brain sagittal cuts T2 1 year after surgery	125

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table 1:	Stages of metastases: roles of tumor cell and target tissue ..	14
Table 2:	Prevalence of Parenchymal Brain Metastases by Primary Tumor	20
Table 3:	Brain metastases incidence of symptoms and signs at diagnosis	26
Table 4:	Differential diagnosis of altered mental status in the cancer patients	29
Table 5:	Comparative Imaging findings of parenchymal metastases in both CT and MRI	39
Table 6:	Differential diagnosis of Solitary brain metastasis	56
Table 7:	Studies evaluating the role of postoperative radiotherapy ..	74
Table 8:	Radiosurgery for brain metatases: results of representative series	76
Table 9:	Karnofsky scale (modified)	91
Table 10:	Glasgow Coma Scale	91
Table 11:	Paired t-test to study the difference of karnofski scores before and after surgery followed by WBRT	97

Table 12: Paired t-test study the difference of tumor size before and after surgery followed by WBRT	97
Table 13: The variables are described in a regression model	98
Table 14: The results of the regression model using backward elimination method	99

ABSTRACT

Brain metastases are a common complication in cancer patients. In this work, 30 patients with supratentorial solitary brain metastases are evaluated retrospectively, The modality of therapy: Surgery followed by whole brain radiotherapy. Results of both therapies, including efficacy, toxicity /morbidity and survival, quality of life and cost benefit will be evaluated.

Key Words:

Brain metastases

Surgery

Whole Brain Radiotherapy

INTRODUCTION

Brain metastases are the most common brain tumor seen clinically representing slightly more than half of brain tumor patients and an important cause of morbidity and mortality. They develop in approximately 10% to 30% of adults and 6% to 10% of children with cancer

In adults, the primary tumors most often responsible for brain metastases are lung cancer (50%), breast cancer (15% to 20%), unknown primary tumor (10% to 15%), melanoma (10%), and colon cancer.

In children, the most common sources of brain metastasis are sarcomas, neuroblastoma, and germ cell tumors

Approximately 80% of brain metastases are located in the cerebral hemispheres, 15% in the cerebellum, and 5% in the brainstem (*Biswas et al., 2006*).

Clinical Manifestations

The clinical features of brain metastases are extremely variable, and the presence of brain metastases should be suspected in any cancer patient who develops new neurological symptoms.

The clinical presentation of brain metastases is similar to that of other brain tumors and includes headache, focal neurological dysfunction, cognitive dysfunction, and seizures

Brain metastases must be distinguished from primary brain tumors, abscesses, demyelination, cerebral infarctions or hemorrhage and progressive multifocal leukoencephalopathy. Moreover brain metastases must be differentiated from the effects of prior treatment, including radiation necrosis (*Bruce-Staskal & Bouton, 2001*).

The best diagnostic test for brain metastases is contrast-enhanced Magnetic resonance imaging (MRI). This test is more sensitive than enhanced CT scanning or nonenhanced MRI in detecting lesions in patients suspected of having cerebral metastases, and in differentiating these metastases from other central nervous system (CNS) lesions. There is also new diagnostic methods as MRI spectroscopy, functional MRI is extremely helpful as it demonstrates the relations of the mass to the eloquent cortical areas and white matter fibers. Further advanced techniques have therefore been combined with diffusion imaging in this increased sensitivity, most commonly used is MRI spectroscopy which provides information about the metabolic profile inside and in areas around the lesion (*Han, Huang, Guo, Zhuang, & Han, 2015*).

In the majority (80%) of patients, brain metastases develop after the diagnosis of primary cancer (metachronous presentation). However, in some patients, brain metastases may be diagnosed before the primary tumor is found (precocious presentation) or at the same time as the primary is detected (synchronous presentation) (*T. Batchelor & DeAngelis, 1996*).

Management Goals

A) Symptomatic Therapy

i- Corticosteroids

Corticosteroids produce their antiedema effect by reducing the permeability of tumor capillaries, and are indicated in any patient with symptomatic edema

ii- Anticonvulsants

Seizures are the presenting symptom in approximately 10% to 20% of patients with brain metastases, and occur at some stage of the illness in another 10% to 20% of patients

iii- Treatment of Venous Thromboembolic Disease

Venous thromboembolic disease is common in patients with brain metastases, occurring in approximately 20% of patients. The optimal therapy is unknown (*T. T. Batchelor & Byrne, 2006*).

B) Definitive Treatment

I-Surgery

Indications of surgical excision of solitary lesion:

- Lesion is accessible.
- Lesion is symptomatic or life threatening.
- Diagnosis is unknown: alternatively considered as biopsy. e.g. Stereotactic biopsy (*Tajran & Berek, 2003*).

Patients with multiple brain metastases generally have worse survival than those with solitary lesions. Multiple brain metastasis are usually treated with radiosurgery without surgery.

In these cases, indications of surgery include:

- One accessible symptomatic and /or life threatening lesion. e.g. post. Fossa or large temporal lesion.
- Multiple lesions that can all be completely removed surgically.
- No identifiable primary (*Iida et al., 2014*).

II- Radiation Therapy

i- Overall, conventional whole-brain radiation therapy (WBRT) increases the median survival to 3 to 6 months. Radiation is effective in the palliation of neurological symptoms and also significantly decreases the likelihood of death due to neurological causes. The main goal of radiation therapy is to improve the neurological deficits caused by the tumor deposit and induce growth restraint of these metastatic deposits (*Saito et al., 2006*)

ii - Stereotactic Radiosurgery

Stereotactic radiosurgery is a technique of external irradiation that utilizes multiple convergent beams to deliver a high single dose of radiation to a radiographically discrete treatment volume. Radiosurgery can be performed with high-energy x-rays produced by linear accelerators, with gamma rays emitted by radioactive Cobalt source using the Gamma Knife machine, and, less frequently, with charged particles,

such as protons, produced by cyclotrons. Stereotactic radiosurgery is used as a boost to brain metastases after WBRT (*Boyd & Mehta, 1999*).

iii- Interstitial Brachytherapy

Interstitial brachytherapy involves the implantation of locally active radioisotope into a tumor or the wall of the surgical cavity, with the objective of delivering an additional dose of radiation to the residual tumor while limiting the amount of radiation to the surrounding brain (*McDermott, Cosgrove, Larson, Sneed, & Gutin, 1996*).

III- Chemotherapy

Cytotoxic chemotherapy has been considered ineffective for brain metastasis, traditionally because of poor penetration across the blood-brain barrier.

However, cytotoxic chemotherapy could be effective in some specific situation, e.g. macroscopic brain metastasis of chemosensitive disease, such as: small cell lung cancer, germ cell tumor and breast cancer.

Recently, tyrosine kinase inhibitors targeting epidermal growth factor receptor (EGFR), (gefitinib and erlotinib) or human epidermal growth factor receptor 2 (HER 2), have a promising activity to brain metastasis of lung cancer with activating EGFR mutations or breast cancer with HER 2 overexpression (*Bai & Han, 2013*).

V-Hormonal therapy:

This can be used as a part of treatment regimen especially in patients with hormone-responsive tumors, such as breast cancer (*Wang et al., 2014*).

Prognosis

The median survival of patients with untreated brain metastases is approximately 1 month. Addition of steroids increases survival to 2 months, whole-brain radiation further improves survival to 3 to 6 months. Favorable prognostic factors include the absence of systemic disease, young age (<60 years old), good performance status (Karnofsky performance status ≥ 70), long time to the development of metastasis, surgical resection, and the number of lesions is 3 or less (*Auchter et al., 1996*).